The Promise of Antibody Treatments
When the immune system encounters a virus, it builds proteins called antibodies that attach to the virus and neutralize it. Monoclonal antibody drugs (mAbs) are lab-made versions of those proteins, engineered to target a specific part of the virus — in this case, the spike protein that SARS-CoV-2 uses to enter cells.
Several mAb treatments proved useful earlier in the pandemic. For people who couldn't mount their own immune response — like transplant recipients or people on immunosuppressive drugs — some of these drugs offered meaningful protection. But treating people already hospitalized with severe disease is a different challenge.
What Made This Drug Different
Tixagevimab-cilgavimab is a combination of two antibodies that attach to different parts of the virus spike protein. The idea is that by targeting two sites at once, the drug would be harder for the virus to escape and would neutralize it more effectively. Think of it like two padlocks on the same door — the virus would need to change both at once to slip through.
But here's the twist: the clinical reality didn't match the biological logic. The drug looked promising in lab studies and in prevention trials for some high-risk patients. When tested in people already hospitalized with COVID, however, it didn't move the needle on outcomes that matter to patients.
About the DisCoVeRy Trial
This was a phase 3 clinical trial — the gold standard of drug testing — conducted across multiple centers. A total of 237 hospitalized adults with confirmed COVID-19 were randomly assigned to receive either tixagevimab-cilgavimab (123 patients) or a placebo (110 patients) and were followed for up to 456 days — more than 15 months. Researchers measured clinical status, hospital outcomes, deaths, and whether patients were readmitted to the hospital. They also tracked how long the drug stayed in the bloodstream and whether the immune system produced antibodies against the drug itself.
The primary goal was to see whether patients in the treatment group had better clinical status at day 15. They did not. There was no meaningful difference between those who received the drug and those who received the placebo.
Mortality, reinfection rates, and adverse events were similar in both groups. Interestingly, the drug did work biologically — blood levels remained detectable for up to 365 days, and the antibody successfully produced higher neutralizing activity in blood samples for up to six months. That means the drug did what it was supposed to do in the bloodstream. But that biological activity did not translate into clinical improvement.
This is an important reminder that a drug working in the lab — or even in the blood — doesn't always mean it helps patients feel better or survive.
One Concerning Signal
There was one unexpected finding: in the broader group of participants, those who received tixagevimab-cilgavimab had about twice the rate of hospital readmission after discharge compared to placebo. However, when the analysis was restricted to patients who were confirmed antibody-positive at the start (meaning the test confirmed active infection), that difference was no longer statistically significant. Researchers believe the broader result may reflect a chance finding or differences in the populations analyzed, not a true harm of the drug.
What This Means for the Bigger Picture
Negative results matter. The history of medicine is full of treatments that made biological sense but failed in clinical trials — and the pandemic accelerated that process, generating data on dozens of drugs in record time. Tixagevimab-cilgavimab had already been withdrawn from use for treatment by the time these results were published, largely because of viral evolution: the Omicron variants that became dominant proved largely resistant to the drug's antibodies. This trial confirms that the drug would not have been the answer anyway, even with fully susceptible variants.
If you or a family member was hospitalized with COVID and received this drug during the pandemic, this data provides reassurance that it was safe over the long term. It didn't help, but it also didn't harm. For people currently seeking COVID treatments, other antiviral options (like nirmatrelvir-ritonavir, known as Paxlovid) and updated vaccines remain the primary tools recommended by health authorities.
The trial enrolled participants between 2021 and 2022, when both pre-Omicron and early Omicron variants were circulating. That mix of variants makes it harder to draw conclusions about any single viral strain. The study was also relatively small — 237 participants — which limits the ability to detect modest benefits or harms. And because most participants were infected during a specific window of the pandemic, results may not apply to later variants or to COVID as it circulates today.
This trial closes a chapter on one of many COVID antibody strategies that were pursued during the pandemic. Its lasting value lies in the detailed pharmacokinetic and immunogenicity data — information about how long the drug stays in the body and how the immune system responds to it — which can inform the design of future antibody treatments. As new variants emerge, researchers will continue refining which patients, which viral targets, and which drug structures offer the best chance of meaningful clinical benefit.
